Pathos AI closes $237M Series E led by Bristol Myers Squibb at about a $3B valuation
Pathos AI closed a $237 million Series E led by Bristol Myers Squibb at about a $3 billion post-money valuation and signed an Alzheimer's data deal with Tempus.
By Emre AlemdarPublished
Tech AI LatestPathos AI, a New York company that uses AI agents to develop its own drugs, closed a $237 million Series E on 23 October 2026 at a post-money valuation of approximately $3 billion. Bristol Myers Squibb led the round with existing investors. In a parallel deal, BMS gains access to Pathos's Foundry platform and Pathos will license a neurology dataset from Tempus AI for $55 million over five years, starting with Alzheimer's disease.
Key facts
- Announced: 23 October 2026 (Pathos AI press releases)
- Round: $237 million Series E, closed, at a post-money valuation of approximately $3 billion
- Lead investor: Bristol Myers Squibb, with participation from existing investors
- Priority: advancing JSKN016, a TROP2/HER3 bispecific antibody-drug conjugate, toward registrational studies
- Side deal: five-year, $55 million license for a Tempus AI neurology dataset; BMS gets three-year exclusive neuroscience rights to Foundry
- Not stated: names of the existing investors and the previous valuation
What Pathos AI announced
Pathos AI announced on 23 October 2026 the closing of a $237 million Series E financing at a post-money valuation of approximately $3 billion. Bristol Myers Squibb (NYSE: BMY) led the round, with participation from existing investors the release does not name. Pathos describes itself as a clinical-stage AI and technology company that advances its own pipeline of drugs.
The company says it used its AI platform, Foundry, to expand its clinical-stage oncology portfolio through a series of rapid deals over recent months. Its pipeline now has four active clinical assets. The proceeds will scale Foundry and speed up clinical development, with JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate, moving toward registrational studies. The money also covers pocenbrodib in prostate cancer and multiple myeloma, AZD4241, an ER PROTAC partnered with AstraZeneca, and DO-2, a MET kinase inhibitor.
The Bristol Myers Squibb and Tempus deals
A second release the same day set out multi-year collaborations with BMS and Tempus AI on Alzheimer's disease and other neurological conditions. Tempus will build a de-identified, longitudinal dataset from hundreds of thousands of patients, and Pathos will license it under a five-year, $55 million agreement. BMS gains non-exclusive access to Pathos Foundry across its broader portfolio and three-year exclusive rights to use it for neuroscience development.
"Our investment in Pathos reflects our commitment to applying advanced AI and data science across research and development," said Simon Davies, SVP and Head of Data and Quantitative Sciences at BMS. Pathos CEO Iker Huerga said Foundry has accelerated the company's ability to find promising clinical assets and add them to its pipeline.
Why it matters
Pathos is betting that AI agents can improve the odds of a drug succeeding in trials by choosing the right patients and programs, rather than by discovering new molecules. Having a large drugmaker lead the round and buy platform access at the same time gives that claim a paying customer. Foundry runs thousands of specialized agents that combine clinical, genomic and competitive data to pick the next decision for a program, according to the company. The release gives no evidence yet on trial outcomes. Tempus CEO Eric Lefkofsky said progress against Alzheimer's requires unprecedented data scale and computing power, which is what the three-way arrangement is meant to supply.
What to watch next
The next markers are the start of a registrational study for JSKN016 and the first output from the Alzheimer's dataset. Neither has a date in the releases. The round sits on the AI funding tracker next to Legora's Series E two days earlier, with more rounds under AI Business & Funding.
What changed
| Before | Pathos AI applied its Foundry platform to its own oncology pipeline, with no neuroscience program or BMS platform deal |
|---|---|
| After | Pathos AI has $237 million of new capital at about a $3 billion post-money valuation, BMS as lead investor and platform customer, and a neurology dataset deal with Tempus |
| Who it affects | Pathos's clinical programs and partners, BMS neuroscience teams, and other AI drug development companies |
Questions people ask
- Who led Pathos AI's Series E?
- Bristol Myers Squibb led the $237 million round, with participation from existing investors.
- What is Pathos AI worth?
- Approximately $3 billion post-money after the Series E, according to the company's release of 23 October 2026.
- What will Pathos do with the money?
- Scale its Foundry AI platform and advance its clinical pipeline, with JSKN016 moving toward registrational studies as a key priority.
Sources
Reference pages
- Pathos AI company
Spotted an error? See the corrections policy and tell the editor. Facts in this story come from the sources listed above; vendor claims are attributed.
Comments
Loading comments.
